As of today (2024-04-24), the Trailing Annual Dividend Yield of Nabriva Therapeutics is 0.00%.
The historical rank and industry rank for Nabriva Therapeutics's Dividend Yield % or its related term are showing as below:
NBRVF's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.625 * Ranked among companies with meaningful Dividend Yield % only.
Nabriva Therapeutics's Dividend Payout Ratio for the
three
months ended in Jun. 2023 was 0.00.
Nabriva Therapeutics's Dividends per Share for the
three
months ended in Jun. 2023 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Nabriva Therapeutics Dividend Yield % Historical Data
The historical data trend for Nabriva Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nabriva Therapeutics's Dividend Yield %
For the Biotechnology subindustry, Nabriva Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's Dividend Yield % falls into.
Nabriva Therapeutics Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Nabriva Therapeutics Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 